Google Platform Changes Spur Pharma Rethinking Of Search Engine Ads
This article was originally published in The Tan Sheet
Widespread use of paid ads that display disease-specific website address differing significantly from destination hyperlink for branded product will end in January.
You may also be interested in...
Google Creates New Formats To Include Risk Information In Sponsored Search Results
Click-through rate on health condition search results declined dramatically since FDA citations, company says.
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links
Firms will need to redesign sponsored links that appear on Internet search engines or forgo using them at all, food and drug attorneys suggest following the agency's recent cluster of letters citing the promotions
Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review
‘Clear signal’ in the ATLAS study of presymptomatic, SOD1 mutation carriers could provide evidence needed to confirm tofersen’s benefit in symptomatic ALS patients, FDA’s Teresa Buracchio says, adding that getting confirmatory evidence from the VALOR open-label extension 'could be a little more tricky.'